Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ApexOnco Front Page
Recent articles
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
“We need all the capital we can get our hands on," the company states.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
